Capricor Therapeutics Inc

Capricor Therapeutics Inc (CAPR)

$5.18
-0.38 (-6.83%)
Neutral
Symbol CAPR
Price 5.18$
Beta 6.934
Volume Avrg. 2.69M
Market Cap 0.10B
Shares (2019) 3,711.33K
Last Div 0
Dividend Yield -
DCF Unlevered -56.72 Strong Sell
DCF Levered -52.93 Strong Sell
ROE -111.73% Strong Sell
ROA -68.76% Strong Sell
Operating Margin -769.79% Strong Sell
Debt / Equity 62.49% Buy
P/E -0.75
P/B 0.84 Buy

Retained Earning Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Retained Earnings (Previous Year) -26-34-40-45-7-16-22-35-54-52-67
Net Income -8-6-5-2-9-6-13-192-15-8
Stock Dividends ---39-0-0-0-
Dividend Paid -----------
Retained Earnings -34-40-45-7-16-22-35-54-52-67-74

PPE Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Gross PPE 00000000001
Annual Depreciation --0-000000-01-0
Capital Expenditure -0---0-0-0-0-0-0-0-
Net PPE 00000000010

Intangible and Goodwill Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) 00--0222000
New Purchases -----0--18-18-19-18-6
Intangible and Goodwill 0--02220000

About


Dr. Linda Marban
Healthcare
Biotechnology
NASDAQ Capital Market

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. The company is headquartered in Beverly Hills, California and currently employs 18 full-time employees. The firm focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.